Role of primary care physicians in intrathecal pain management: a narrative review of the literature

References

• Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015;156:1003–1007.
   PubMed Web of Science ®Google Scholar
• Committee on Advancing Pain Research Care and Education, Institute of Medicine of the National Academies. Relieving pain in America: a blueprint for transforming prevention, care, education, and research. Washington (DC): The National Academies Press; 2011.
   Google Scholar
• Nahin RL. Estimates of pain prevalence and severity in adults: United States, 2012. J Pain. 2015;16:769–780.
   PubMed Web of Science ®Google Scholar
• Kaye AD, Baluch A, Scott JT. Pain management in the elderly population: a review. Ochsner J. 2010;10:179–187.
   PubMedGoogle Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain–United States, 2016. MMWR Recomm Rep. 2016;65:1–49.
   PubMed Web of Science ®Google Scholar
• Ripamonti CI, Bandieri E, Roila F. Management of cancer pain: ESMO clinical practice guidelines. Ann Oncol. 2011;22:vi69–vi77.
   PubMed Web of Science ®Google Scholar
• Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2008;11:S105–S120.
   PubMed Web of Science ®Google Scholar
• Lee M, Silverman SM, Hansen H, et al. A comprehensive review of opioid-induced hyperalgesia. Pain Physician. 2011;14:145–161.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention. U.S. prescribing rate maps.  Atlanta, GA: CDC; 2017.
   Google Scholar
• Han B, Hedden SL, Kenneth J, et al. Behavioral health trends in the United States: results from the 2014 national survey on drug use and health. Rockville (MD): Substance Abuse and Mental Health Services Administration (SAMHSA); 2015 Sep. (no. HHS Publication No. SMA 15-4927).
   Google Scholar
• Rudd RA, Aleshire N, Zibbell JE, et al. Increases in drug and opioid overdose deaths — United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016;64:1378–1382.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Prescription opioid overdose data. 2017 [cited 2017 Dec 1]. Available from: http://www.cdc.gov/drugoverdose/data/overdose.html
   Google Scholar
• Manchikanti L, Kaye AM, Kaye AD. Current state of opioid therapy and abuse. Curr Pain Headache Rep. 2016;20:34.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. FDA requires strong warnings for opioid analgesics, prescription opioid cough products, and benzodiazepine labeling related to serious risks and death from combined use [news release]. 2016 [cited Feb 27]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm518697.htm
   Google Scholar
• Deer TR, Smith HS, Cousins M, et al. Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. Pain Physician. 2010;13:E175–E213.
   PubMed Web of Science ®Google Scholar
• Deer TR, Caraway DL, Wallace MS. A definition of refractory pain to help determine suitability for device implantation. Neuromodulation. 2014;17:711–715.
   PubMed Web of Science ®Google Scholar
• Manchikanti L, Abdi S, Atluri S, et al. An update of comprehensive evidence-based guidelines for interventional techniques in chronic spinal pain. Part II: guidance and recommendations. Pain Physician. 2013;16:S49–283.
   PubMedGoogle Scholar
• Falowski S, Sharan A. A review on spinal cord stimulation. J Neurosurg Sci. 2012;56:287–298.
   PubMed Web of Science ®Google Scholar
• Verrills P, Sinclair C, Barnard A. A review of spinal cord stimulation systems for chronic pain. J Pain Res. 2016;9:481–492.
   PubMed Web of Science ®Google Scholar
• MacKichan JJ, Doshi DH. Pharmacokinetic considerations for drug delivery. In: Desai A, Lee M, editors. Gibaldi’s drug delivery systems in pharmaceutical care. Bethesda (MD): American Society of Health-System Pharmacists®; 2007. p. 11–22.
   Google Scholar
• Webster LR. The relationship between the mechanisms of action and safety profiles of intrathecal morphine and ziconotide: a review of the literature. Pain Med. 2015;16:1265–1277.
   PubMed Web of Science ®Google Scholar
• Hayek SM, Deer TR, Pope JE, et al. Intrathecal therapy for cancer and non-cancer pain. Pain Physician. 2011;14:219–248.
   PubMed Web of Science ®Google Scholar
• Pope JE, Deer TR. Intrathecal drug delivery for pain: a clinical guide and future directions. Pain Manag. 2015;5:175–183.
   PubMed Web of Science ®Google Scholar
• Bolash R, Mekhail N. Intrathecal pain pumps: indications, patient selection, techniques, and outcomes. Neurosurg Clin N Am. 2014;25:735–742.
   PubMed Web of Science ®Google Scholar
• Infumorph 200, Infumorph 500 (preservative-free morphine sulfate sterile solution). Eatontown (NJ): West-Ward Pharmaceuticals; 2016.
   Google Scholar
• Prialt (ziconotide) solution, intrathecal infusion. Palo Alto (CA): Jazz Pharmaceuticals, Inc.; 2013.
   Google Scholar
• Breuer B, Cruciani R, Portenoy RK. Pain management by primary care physicians, pain physicians, chiropractors, and acupuncturists: a national survey. South Med J. 2010;103:738–747.
   PubMed Web of Science ®Google Scholar
• Upshur CC, Luckmann RS, Savageau JA. Primary care provider concerns about management of chronic pain in community clinic populations. J Gen Intern Med. 2006;21:652–655.
   PubMed Web of Science ®Google Scholar
• Anderson D, Wang S, Zlateva I. Comprehensive assessment of chronic pain management in primary care: a first phase of a quality improvement initiative at a multisite community health center. Qual Prim Care. 2012;20:421–433.
   PubMedGoogle Scholar
• Levy B, Paulozzi L, Mack KA, et al. Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. Am J Prev Med. 2015;49:409–413.
   PubMed Web of Science ®Google Scholar
• Bottros MM, Christo PJ. Current perspectives on intrathecal drug delivery. J Pain Res. 2014;7:615–626.
   PubMed Web of Science ®Google Scholar
• SYNCHROMED® ISOMED® implantable infusion systems. Minneapolis (MN): Medtronic, Inc.; 2016.
   Google Scholar
• Prometra® II programmable pump for use with intrathecal catheter. Mount Olive (NJ): Flowonix Medical Inc.; 2012.
   Google Scholar
• Upadhyay SP, Mallick PN. Intrathecal drug delivery system (IDDS) for cancer pain management: a review and updates. Am J Hosp Palliat Med. 2012;29:388–398.
   PubMed Web of Science ®Google Scholar
• US Department of Defense, US Department of Veterans Affairs. Indications for consultation and referral during opioid therapy. Silver Spring (MD); 2013.
   Google Scholar
• New York State Office of Alcoholism and Substance Abuse Services. Clinical practice guidance number 2012.2: guidance on referral to a pain or addiction specialist. 2012 cited Feb 27]. Available from: https://www.oasas.ny.gov/AdMed/recommend/guide2ref.cfm
   Google Scholar
• Ray WA, Chung CP, Murray KT, et al. Prescription of long-acting opioids and mortality in patients with chronic noncancer pain. Jama. 2016;315:2415–2423.
   PubMed Web of Science ®Google Scholar
• Miller M, Barber CW, Leatherman S, et al. Prescription opioid duration of action and the risk of unintentional overdose among patients receiving opioid therapy. JAMA Intern Med. 2015;175:608–615.
   PubMed Web of Science ®Google Scholar
• Pope JE, Deer TR, Bruel BM, et al. Clinical uses of intrathecal therapy and its placement in the pain care algorithm. Pain Pract. 2016;16:1092–1106.
   PubMed Web of Science ®Google Scholar
• Deer T, Winkelmüller W, Erdine S, et al. Intrathecal therapy for cancer and nonmalignant pain: patient selection and patient management. Neuromodulation. 1999;2:55–66.
   PubMed Web of Science ®Google Scholar
• Bruel BM, Burton AW. Intrathecal therapy for cancer-related pain. Pain Med. 2016;12:2404–2421.
   Web of Science ®Google Scholar
• Deer TR, Pope JE, Hayek S, et al. The Polyanalgesic Consensus Conference (PACC): recommendations on intrathecal drug infusion systems best practices and guidelines. Neuromodulation. 2017;20:96–132.
   PubMed Web of Science ®Google Scholar
• Saulino M, Kim PS, Shaw E. Practical considerations and patient selection for intrathecal drug delivery in the management of chronic pain. J Pain Res. 2014;7:627–638.
   PubMed Web of Science ®Google Scholar
• Ahmed SU, Martin NM, Chang Y. Patient selection and trial methods for intraspinal drug delivery for chronic pain: a national survey. Neuromodulation. 2005;8:112–120.
   PubMed Web of Science ®Google Scholar
• Deer TR, Hayek S, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20:133–154.
   PubMed Web of Science ®Google Scholar
• Deer TR, Pope JE, Hayek S, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for intrathecal drug delivery: guidance for improving safety and mitigating risks. Neuromodulation. 2017;20:155–176.
   PubMed Web of Science ®Google Scholar
• Narouze S, Benzon HT, Provenzano DA, et al. Interventional spine and pain procedures in patients on antiplatelet and anticoagulant medications: guidelines from the American Society of Regional Anesthesia and Pain Medicine, the European Society of Regional Anaesthesia and Pain Therapy, the American Academy of Pain Medicine, the International Neuromodulation Society, the North American Neuromodulation Society, and the World Institute of Pain. Reg Anesth Pain Med. 2015;40:182–212.
   PubMed Web of Science ®Google Scholar
• Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery). American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery), American Society of Echocardiography, American Society of Nuclear Cardiology. Anesth Analg. 2008;106:685–712.
   PubMed Web of Science ®Google Scholar
• Kumar K, Rizvi S, Bishop S. Cost effectiveness of intrathecal drug therapy in management of chronic nonmalignant pain. Clin J Pain. 2013;29:138–145.
   PubMed Web of Science ®Google Scholar
• Dewilde S, Verdian L, Maclaine GD. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK. Curr Med Res Opin. 2009;25:2007–2019.
   PubMed Web of Science ®Google Scholar
• Kumar K, Hunter G, Demeria DD. Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. J Neurosurg. 2002;97:803–810.
   PubMed Web of Science ®Google Scholar
• Rauck RL, Cherry D, Boyer MF, et al. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. J Pain. 2003;4:441–447.
   PubMed Web of Science ®Google Scholar
• Becker R, Jakob D, Uhle EI, et al. The significance of intrathecal opioid therapy for the treatment of neuropathic cancer pain conditions. Stereotact Funct Neurosurg. 2000;75:16–26.
   PubMed Web of Science ®Google Scholar
• Winkelmüller M, Winkelmüller W. Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. J Neurosurg. 1996;85:458–467.
   PubMed Web of Science ®Google Scholar
• Anderson VC, Burchiel KJ. A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. Neurosurgery. 1999;44:289–300.
   PubMed Web of Science ®Google Scholar
• Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20:4040–4049.
   PubMed Web of Science ®Google Scholar
• Staats PS, Yearwood T, Charapata SG, et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. Jama. 2004;291:63–70.
   PubMed Web of Science ®Google Scholar
• Wallace MS, Charapata SG, Fisher R, et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation. 2006;9:75–86.
   PubMed Web of Science ®Google Scholar
• Rauck RL, Wallace MS, Leong MS, et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J Pain Symptom Manage. 2006;31:393–406.
   PubMed Web of Science ®Google Scholar
• Deer T, Rauck RL, Kim P, et al. Effectiveness and safety of intrathecal ziconotide: Interim analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM). Pain Pract. 2018;18:230–238.
   PubMed Web of Science ®Google Scholar
• Webster LR, Fisher R, Charapata S, et al. Long-term intrathecal ziconotide for chronic pain: an open-label study. J Pain Symptom Manage. 2009;37:363–372.
   PubMed Web of Science ®Google Scholar
• Mohammed S, Brookes ME, Eldabe S. Ziconotide for severe neuropathic pain in metastatic breast cancer. J Pain Palliati Care Pharmacother. 2012;26:286–288.
   Google Scholar
• Pope JE, Deer TR. Intrathecal pharmacology update: novel dosing strategy for intrathecal monotherapy ziconotide on efficacy and sustainability. Neuromodulation. 2015;18:414–420.
   PubMed Web of Science ®Google Scholar
• McDowell GC, Pope JE. Intrathecal ziconotide: dosing and administration strategies in patients with refractory chronic pain. Neuromodulation. 2016;19:522–532.
   PubMed Web of Science ®Google Scholar
• Staats PS. Complications of intrathecal therapy. Pain Med. 2008;9:S102–S107.
   Web of Science ®Google Scholar
• Naumann C, Erdine S, Koulousakis A, et al. Drug adverse events and system complications of intrathecal opioid delivery for pain: origins, detection, manifestations, and management. Neuromodulation. 1999;2:92–107.
   PubMed Web of Science ®Google Scholar
• Prager J, Deer T, Levy R, et al. Best practices for intrathecal drug delivery for pain. Neuromodulation. 2014;17:354–372.
   PubMed Web of Science ®Google Scholar
• Ruan X. Drug-related side effects of long-term intrathecal morphine therapy. Pain Physician. 2007;10:357–366.
   PubMedGoogle Scholar
• Charapata SG, Ellis D. Unintentional overdose with intrathecal ziconotide. Pain Med. 2002;3:189–190.
   Google Scholar
• Fisher R, Hassenbusch S, Krames E, et al. A consensus statement regarding the present suggested titration for prialt (ziconotide). Neuromodulation. 2005;8:153–154.
   PubMed Web of Science ®Google Scholar
• Stearns L, Boortz-Marx R, Du Pen S, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3:399–408.
   PubMedGoogle Scholar